newsmetry
rusign inget started
macro

Vir's ECLIPSE 1 trial hits primary and key secondary goals

Vir reports that its ECLIPSE 1 study reached primary and key secondary endpoints, per a TradingView summary of the company's release.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

According to TradingView, Vir's ECLIPSE 1 study met its primary and key secondary targets. In total, 44.1% of participants reached undetectable HDV RNA together with normal ALT levels, while 79.2% reached undetectable HDV RNA at Week 48.

HBsAg dropped under 10 IU/mL in 95.2% of patients. Every participant finished the treatment with no interruptions or early discontinuations.

why it matters

For Vir investors, the readout matters because it supports the drug's performance against hepatitis D at key checkpoints. It may shape how the market values the company's pipeline, but it concerns a single developer rather than the broader market.

market impact

Vir shares: positive trial data supports investor interest in the company's pipeline

  • Vir shares pressure up — meeting key endpoints strengthens the case for the company's drug candidate

tags

StockUnited States

instruments

VIR

on polymarket

Will total votes cast in the 2026 midterm election for Senator from West Virginia be less than 400,000?0.2%Will total votes cast in the 2026 midterm election for Senator from Virginia be 4,000,000 or more?3.9%Will the Democratic Party candidate win the 2026 Virginia Senate election by 15%-18%?1%

sources

  1. VIR: ECLIPSE 1 met both key endpoints, with 79.2% achieving HDV RNA TND at Week 48 — TradingView, 8 November 2026 at 23:33 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories